GliaCure, founded in 2011, is based on discoveries by its scientific founder, Philip Haydon, Ph.D., of Tufts University. It’s business offices are based in Madison, Wisconsin.
GliaCure is a pioneer in the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company’s approaches are based on glial targets, a cell type in the brain that has previously been overlooked in drug discovery.
The company has developed a small molecule clinical candidate – GC021109 – for a glial target that has two primary actions downstream of target engagement: the stimulation of phagocytosis and anti-inflammatory actions in which levels of pro-inflammatory cytokines are reduced.
GC021109 is currently being developed primarily as a disease modifying treatment of Alzheimer’s disease; however, its dual phagocytosis and anti-inflammatory actions have the potential to affect other disorders. In addition to its program using GC021109, GliaCure has a pipeline program for the development of therapeutics for astrocytic targets related to additional disorders, such as depression and sleep consolidation.
GliaCure is a virtual drug discovery company, working with expert consultants and specialists to allow rapid decision-making and to maximize investment. GliaCure has raised over $11 million to date from private investors and charitable foundations such as ADDF.